From Whole-Brain Radiotherapy to Immunotherapy: A Multidisciplinary Approach for Patients with Brain Metastases from NSCLC

Abstract EN

Non-small cell lung cancer patients with brain metastases have a multitude of treatment options, but there is currently no international and multidisciplinary consensus concerning their optimal treatment.

Local therapies have the principal role, especially in symptomatic patients.

Advances in surgery and radiation therapy manage considerable local control.

Systemic treatments have shown effect in clinical trials and in real life clinical settings; yet, at present, this is restricted to patients with asymptomatic or stable intracranial lesions.

Targeted agents can have a benefit only in patients with EGFR mutations or ALK rearrangement.

Immunotherapy has shown impressive results in patients with PD-L1 expression in tumor cells.

Its effects can be further enhanced by a synergy with radiotherapy, possibly by increasing the percentage of responders.

The present review summarizes the need for more effective systemic treatments, so that the increased intracranial control achieved by local treatments can be translated in an increase in overall survival.